We investigated the antimicrobial activity of four polymyxin B components, B1, B2, B3, and isoleucine (Ile)-B1, individually and in combination. B3 was the most active agent against all organisms tested except Acinetobacter baumannii, for which Ile-B1 was most active. One combination met the criteria for synergy, B3 plus Ile-B1. No combinations exhibited antagonism. The dominant components of polymyxin B products (B1 and B2) were associated with the lowest probability of improved antibacterial activity when combined.
P
olymyxin B is manufactured via fermentation from the bacterium Paenibacillus polymyxa (formerly Bacillus polymyxa), and the resulting product, which is utilized clinically, is a heterogeneous mixture composed of up to 30 related polymyxin-like lipopeptides (1) . This heterogeneity has raised concerns about product uniformity (2) (3) (4) . We previously demonstrated variation in both composition and potency among different product manufacturers and lots of polymyxin B (5) . In general, one component alone (B1) comprises two-thirds of the drug; four components together account for Ն80% of the total product: B1, B2, B3, and isoleucine (Ile)-B1 (4, 5) . In order to assess their individual contributions to drug potency, we investigated the antimicrobial activity of four major polymyxin B components tested alone and in each combination of two components.
Four components, polymyxin B1, B2, isoleucine-B1 (Ile-B1), and B3, were obtained from a commercial manufacturer, Toku-E USA (Bellingham, WA, USA) (Fig. 1) . Purity was reported by the manufacturer as 98.5% for B1, 99% for B2, 95.3% for B3, and 90.2% for Ile-B1. The antibacterial activity of each individual component was evaluated with the broth microdilution (BMD) method against groups of Gram-negative organisms: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. The MIC assays were conducted according to Clinical and Laboratory Standards Institute (CLSI) guidelines (6, 7) . Custom MIC panels employing incremental dilutions were produced by JMI Laboratories and used in place of panels with routine log 2 dilutions (8). The component concentrations ranged from 0.03 to 4 g/ml. BMD assays for the non-lactose-fermenting Gram-negative organisms, A. baumannii and P. aeruginosa, were conducted in the presence and absence of the surfactant polysorbate 80 (P-80) (9, 10) . BMD assays for the Enterobacteriaceae (E. coli and K. pneumoniae) were tested without P-80. The lowest reproducible MIC from duplicate testing of the three organisms in each species group for the individual components was compared to the MIC results obtained using a United States Pharmacopeia (USP) reference formulation of polymyxin B (USP lot L0H010). Utilizing ultra-high-performance liquid chromatography mass spectrometry (UPLC MS), we identified 66.9% polymyxin B1 and 15.9% polymyxin B2 in USP lot L0H010. The quantities of Ile-B1 and B3 were not determined due to the reduced accuracy of the assay to detect these less-abundant components.
The following combinations of two polymyxin B components were evaluated in checkerboard assay susceptibility tests: B1/Ile-B1, B1/B2, B1/B3, B2/Ile-B1, B2/B3, and B3/Ile-B1. Dilutions ranged from 0.06 to 4 g/ml for both drug components when evaluations were conducted in Mueller-Hinton broth without 0.002% P-80. Twelve strains of Gram-negative clinical pathogens were tested (in duplicate). Combination activity was defined using the following five categories: synergy, Ն4-fold lowering of each component MIC when combined (Α fractional inhibitory Antimicrobial activity assays of the individual polymyxin B components determined that B3 was the most potent against all organisms tested except A. baumannii. Ile-B1 was most active against A. baumannii. B1 was the least potent against all organisms tested except A. baumannii. Overall, the MIC results among the individual components ranged from 50 to 150% of those obtained against the same organisms when tested against USP lot L0H010 (Fig. 2) . The greatest MIC variation was observed among the nonfermentative Gram-negative bacilli. The addition of P-80 to BMD incremental assays for the nonfermenting organisms led to an average MIC reduction of 8-fold (approximately 90%) compared to MIC results determined without P-80 (data not shown). In the presence of P-80, B3 remained the most active against P. aerugi-nosa, and Ile-B1 was again the most active component tested against A. baumannii.
In checkerboard synergy analyses, only one combination and strain met the criterion for synergy, B3 plus Ile-B1 against E. coli (ΑFIC, 0.5). No combinations exhibited antagonism. Combinations employing B3 and/or Ile-B1 demonstrated the greatest occurrence rates of partial synergy or enhanced inhibition. The B1/B2 combination was least likely to show any level of improved activity (13%), with a 42% occurrence of indifference. This was in contrast to 0 to 8% indifference and 42 to 67% partial or complete synergy rates for all non-B1 combinations (Table 1 ).
Our data demonstrate that the greatest antimicrobial activity was found among the minor components of polymyxin B. Component B3 had the lowest MICs when tested against each organism group, except A. baumannii; Ile-B1 was most potent against A. baumannii. The reduction in MIC between the USP reference and the most active components ranged from 30 to 50%. At the outset, this difference may seem minor and clinically irrelevant, particularly recognizing that MIC test variation may be within one doubling dilution of the true value using a BMD method. However, strategies to dose polymyxin B rely heavily on an accurately determined MIC (11) . A 30 to 50% difference in potency, as measured by a reproducible MIC test, might alter an optimal polymyxin B dose (11, 12) . Thus, polymyxin B composition changes might impact clinical success or toxicity issues.
Checkerboard analyses indicated that the dominant components of polymyxin B products (B1 and B2) are those associated with the lowest probability of improved antibacterial activity when combined. While these results should be confirmed with additional investigations, including time-kill studies, these preliminary data indicate that the formulation of polymyxin B could be refined to maximize antimicrobial activity. With respect to differences in toxicity attributable to individual polymyxin B components, Abdelraouf et al. (13) reported that variations in the concentrations of polymyxin B1, Ile-B1, B2, and B3 in rat renal tissue, following intravenous administration of polymyxin B, were consistent with the relative abundance of the components in the USP formulation of the drug. These inves- tigators concluded there was no preferential accumulation of any one component (13) .
While a previous investigation (3) examined the potency of individual polymyxin B components, this is the first to evaluate potency variation across a broad range of pathogens and among defined combinations of the individual polymyxin B components. Our data indicate that adjustments in the composition of polymyxin B to increase the abundance of the more active minor components may enhance the antimicrobial properties of this pharmaceutical agent. 
